ATOD
MCID: DRM053
MIFTS: 71

Dermatitis, Atopic (ATOD)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Dermatitis, Atopic

MalaCards integrated aliases for Dermatitis, Atopic:

Name: Dermatitis, Atopic 57 29 44 73
Atopic Dermatitis 12 76 25 37 6 15
Atopic Eczema 12 25 15
Dermatitis, Atopic, Susceptibility to, 1 57
Atopic Neurodermatitis 12
Dermatitis, Atopic, 1 13
Dermatitis, Atopic 1 57
Allergic Dermatitis 12
Besnier's Prurigo 12
Dermatitis Atopic 55
Eczema, Atopic 57
Allergic 12
Eczema 73
Atod 57

Characteristics:

OMIM:

57
Miscellaneous:
food intolerance
diagnosis requires 3 major features (a positive family history is also considered a major feature) and at least 3 minor features

Inheritance:
autosomal dominant


HPO:

32
dermatitis, atopic:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Dermatitis, Atopic

Genetics Home Reference : 25 Atopic dermatitis (also known as atopic eczema) is a disorder characterized by inflammation of the skin (dermatitis). The condition usually begins in early infancy, and it often disappears before adolescence. However, in some affected individuals the condition continues into adulthood; in others, it does not begin until adulthood. Hallmarks of atopic dermatitis include dry, itchy skin and red rashes that come and go. The rashes can occur on any part of the body, although the pattern tends to be different at different ages. In affected infants, the rashes commonly occur on the face, scalp, hands, and feet. In children, the rashes are usually found in the bend of the elbows and knees and on the front of the neck. In adolescents and adults, the rashes typically occur on the wrists, ankles, and eyelids in addition to the bend of the elbows and knees. Scratching the itchy skin can lead to oozing and crusting of the rashes and thickening and hardening (lichenification) of the skin. The itchiness can be so severe as to disturb sleep and impair a person's quality of life.

MalaCards based summary : Dermatitis, Atopic, also known as atopic dermatitis, is related to dermatitis, atopic, 3 and churg-strauss syndrome, and has symptoms including pruritus and exanthema. An important gene associated with Dermatitis, Atopic is MIR155 (MicroRNA 155), and among its related pathways/superpathways are PEDF Induced Signaling and Allograft rejection. The drugs Montelukast and Petrolatum have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are cataract and ichthyosis

Disease Ontology : 12 A dermatitis that is a chronically relapsing inflammatory allergic response located in the skin that causes itching and flaking.

OMIM : 57 Atopic dermatitis (ATOD), also known as eczema, is a common chronic pruritic inflammatory skin disease with a strong genetic component. Onset typically occurs during the first 2 years of life (review by Soderhall et al., 2007). (603165)

Wikipedia : 76 Atopic dermatitis (AD), also known as atopic eczema, is a type of inflammation of the skin (dermatitis).... more...

Related Diseases for Dermatitis, Atopic

Diseases in the Dermatitis, Atopic family:

Dermatitis, Atopic, 2 Dermatitis, Atopic, 3
Dermatitis, Atopic, 4 Dermatitis, Atopic, 5
Dermatitis, Atopic, 6 Dermatitis, Atopic, 7
Dermatitis, Atopic, 8 Dermatitis, Atopic, 9

Diseases related to Dermatitis, Atopic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 946)
# Related Disease Score Top Affiliating Genes
1 dermatitis, atopic, 3 34.2 ATOD3 FLG
2 churg-strauss syndrome 33.3 CCL17 IL5 RNASE3
3 milk allergy 32.9 IL4 IL5 RNASE3
4 pollen allergy 32.9 IL13 IL4R IL5 RNASE3
5 egg allergy 32.9 IL4 IL5
6 eczema herpeticum 32.8 FLG TSLP
7 hypereosinophilic syndrome 32.4 CCL17 IL13 IL4 IL5 RNASE3
8 nut allergy 32.3 FLG IL5
9 drug allergy 32.3 IL4R IL5 MS4A2
10 giant papillary conjunctivitis 31.9 IL4 RNASE3
11 food allergy 31.8 FLG IL13 IL4 IL5 MS4A2 RNASE3
12 dermatitis 31.8 CCL17 CMA1 FLG IL13 IL31 IL4
13 sulfamethoxazole allergy 31.7 IL4 IL5
14 sinusitis 31.5 IL4R IL5 RNASE3
15 skin disease 31.3 CCL17 FLG IL13 IL31 IL4 IL5
16 ige responsiveness, atopic 31.2 IL13 IL4 IL4R IL5 MS4A2 RNASE3
17 conjunctivitis 31.0 IL13 IL4 IL5 MS4A2 RNASE3
18 allergic asthma 30.9 CCL17 IL13 IL4 IL4R IL5 MS4A2
19 pulmonary eosinophilia 30.9 CCL17 IL13 IL4 IL5 RNASE3
20 blepharoconjunctivitis 30.9 CMA1 IL4 RNASE3
21 keratoconjunctivitis 30.8 CCL17 IL13 IL4 IL5 RNASE3
22 gastroenteritis 30.8 IL4 IL5 RNASE3 TSLP
23 eosinophilic gastroenteritis 30.8 IL5 RNASE3 TSLP
24 conjunctival disease 30.8 IL13 IL4 IL5 MS4A2 RNASE3
25 penicillin allergy 30.7 IL13 IL4 IL4R
26 respiratory allergy 30.7 IL13 IL4 IL4R IL5 MS4A2 RNASE3
27 allergic hypersensitivity disease 30.7 CCL17 FCER2 IL13 IL4 IL4R IL5
28 latex allergy 30.6 FLG IL13 IL4 IL5 RNASE3
29 esophagitis 30.6 IL13 IL5 TSLP
30 allergic contact dermatitis 30.6 CCL17 FLG IL31 IL4 IL5
31 contact dermatitis 30.6 CCL17 FLG IL31 IL4 IL5
32 irritant dermatitis 30.6 FLG MS4A2
33 atopic keratoconjunctivitis 30.6 IL4 IL5 RNASE3
34 cow milk allergy 30.6 IL5 RNASE3
35 common cold 30.6 IL13 IL5 RNASE3 TSLP
36 asthma 30.6 CCL17 FCER2 FLG IL13 IL31 IL4
37 epidermolysis bullosa pruriginosa 30.5 FLG IL31
38 esophagitis, eosinophilic, 1 30.4 FLG IL13 IL5 TSLP
39 vernal keratoconjunctivitis 30.4 IL13 IL4 IL5 RNASE3
40 nickel allergic contact dermatitis 30.4 IL13 IL4 IL5
41 rhinitis 30.4 IL13 IL4 IL4R IL5 RNASE3
42 allergic conjunctivitis 30.4 IL13 IL4 IL5 RNASE3
43 bronchiolitis 30.4 IL13 IL4 IL4R IL5 RNASE3
44 ascaris lumbricoides infection 30.4 IL13 IL5 TSLP
45 allergic rhinitis 30.4 IL13 IL4 IL4R IL5 MS4A2 RNASE3
46 chronic conjunctivitis 30.4 CMA1 FCER2 IL13 IL4 IL5 RNASE3
47 allergic bronchopulmonary aspergillosis 30.4 CCL17 IL4 IL5
48 aspergillosis 30.4 CCL17 IL4 IL5
49 urticaria 30.3 CMA1 FCER2 RNASE3
50 intrinsic asthma 30.3 FCER2 IL4 IL5 RNASE3

Graphical network of the top 20 diseases related to Dermatitis, Atopic:



Diseases related to Dermatitis, Atopic

Symptoms & Phenotypes for Dermatitis, Atopic

Symptoms via clinical synopsis from OMIM:

57
Skin Nails Hair Skin:
ichthyosis
facial erythema
keratosis pilaris
xerosis
pruritus (major feature)
more
Head And Neck Nose:
allergic rhinitis

Immunology:
elevated ige

Head And Neck Eyes:
keratoconus
cataracts (anterior- subcapsular)
conjunctivitis (recurrent)
orbital darkening

Respiratory Airways:
bronchial asthma

Laboratory Abnormalities:
immediate (type i) skin test reactivity


Clinical features from OMIM:

603165

Human phenotypes related to Dermatitis, Atopic:

32 (show all 17)
# Description HPO Frequency HPO Source Accession
1 cataract 32 HP:0000518
2 ichthyosis 32 HP:0008064
3 abnormality of metabolism/homeostasis 32 HP:0001939
4 pallor 32 HP:0000980
5 pruritus 32 HP:0000989
6 dry skin 32 HP:0000958
7 asthma 32 HP:0002099
8 conjunctivitis 32 HP:0000509
9 eczema 32 HP:0000964
10 keratoconus 32 HP:0000563
11 recurrent skin infections 32 HP:0001581
12 allergic rhinitis 32 HP:0003193
13 atopic dermatitis 32 HP:0001047
14 infra-orbital fold 32 HP:0011232
15 facial erythema 32 HP:0001041
16 food intolerance 32 HP:0012537
17 flexural lichenification 32 HP:0007453

UMLS symptoms related to Dermatitis, Atopic:


pruritus, exanthema

Drugs & Therapeutics for Dermatitis, Atopic

Drugs for Dermatitis, Atopic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 387)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4,Not Applicable 158966-92-8 5281040
2
Petrolatum Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 8009-03-8
3
Desonide Approved, Investigational Phase 4,Phase 3 638-94-8 5311066
4
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6, 75614-87-8 774
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
6
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 302-25-0
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
8
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable 2921-57-5
9
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 378-44-9 9782
10
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-03-3
11
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
12
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
13
Pimecrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137071-32-0 6447131 17753757
14
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 124-94-7 31307
15
Fluocinonide Approved, Investigational Phase 4,Phase 2 356-12-7 9642
16 tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2
17
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 94-09-7, 1994-09-7 2337
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
19
Fluticasone Approved, Experimental Phase 4,Phase 3,Early Phase 1 90566-53-3 62924
20
Desoximetasone Approved Phase 4 382-67-2 5311067
21
Cortisone acetate Approved, Investigational Phase 4,Phase 2 1950-04-4, 50-04-4 5745
22
Levocetirizine Approved Phase 4,Phase 3 130018-77-8 1549000
23
Cetirizine Approved Phase 4,Phase 3,Phase 2 83881-51-0 2678
24
Methylprednisolone aceponate Approved, Vet_approved Phase 4,Phase 2 86401-95-8
25
Zinc Approved, Investigational Phase 4 7440-66-6
26
Coal tar Approved Phase 4 8007-45-2
27
Zinc oxide Approved Phase 4 1314-13-2
28
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 1 242138-07-4
29
Glycerol Approved, Investigational Phase 4,Phase 3,Not Applicable 56-81-5 753
30
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
31
Racepinephrine Approved Phase 4,Phase 2 329-65-7 838
32
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
33
mometasone furoate Approved, Vet_approved Phase 4,Phase 2,Phase 1 83919-23-7
34
Alitretinoin Approved, Investigational Phase 4 5300-03-8 449171 444795
35
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
36
Chitosan Approved Phase 4,Phase 2,Not Applicable 9012-76-4 71853
37
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
38
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 10909430 439542
39
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
40
Insulin glulisine Approved Phase 4 207748-29-6
41
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 50-14-6 5280793
42
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 67-97-0 5280795 6221
43
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 1406-16-2
44
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
45
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Not Applicable 2920-86-7
46
Lactitol Investigational Phase 4 585-86-4 3871
47
Cortisone Experimental Phase 4,Phase 2 53-06-5 222786
48
Enoxolone Investigational Phase 4,Not Applicable 471-53-4 18526330
49
BCG vaccine Investigational Phase 4
50 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 782)
# Name Status NCT ID Phase Drugs
1 Does Treatment With Montelukast Improve Symptoms of Atopic Dermatitis in Children? Unknown status NCT02534467 Phase 4 Montelukast
2 Effectiveness of a Combined Dermatological Treatment in Children With Atopic Dermatitis Unknown status NCT02920411 Phase 4
3 Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD) Unknown status NCT01781663 Phase 4
4 Effect of Moisturizing Creams on Skin Barrier Function Unknown status NCT00771121 Phase 4 urea/lactic acid;Placebo
5 Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis Completed NCT02732314 Phase 4 Investigational OTC Cream;0.05% Desonide Cream
6 Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy Withdrawn NCT00871208 Phase 4 Altabax (R);Vehicle and Locoid lipocream (R)
7 An Efficacy and Safety Study of Tacrolimus Ointment in Adult Participants With Atopic Dermatitis Completed NCT01828879 Phase 4 Tacrolimus
8 An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis Completed NCT01782729 Phase 4 Tacrolimus
9 Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis Completed NCT00117377 Phase 4 Pimecrolimus;Placebo
10 Topical Steroid Formulation and Wet Wraps Completed NCT02680301 Phase 4 0.1% triamcinolone CREAM;0.1% triamcinolone OINTMENT
11 A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis Completed NCT01049243 Phase 4 Fluocinonide Cream 0.1%
12 Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting Completed NCT00509990 Phase 4 Pimecrolimus
13 A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis Completed NCT00666302 Phase 4 tacrolimus ointment;pimecrolimus cream
14 Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis Completed NCT00666159 Phase 4 tacrolimus ointment;pimecrolimus cream
15 Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis Completed NCT00667160 Phase 4 tacrolimus ointment;pimecrolimus cream
16 Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application Completed NCT01063218 Phase 4
17 Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects Completed NCT00139581 Phase 4 Pimecrolimus;Pimecrolimus
18 Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis Recruiting NCT03389893 Phase 4 Dupilumab;Placebo
19 Investigation of Flare and Remission in Subjects With Atopic Dermatitis Not yet recruiting NCT03710044 Phase 4 Cyclosporine A
20 The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients Recruiting NCT03667014 Phase 4 Dupilumab
21 Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis Completed NCT00121381 Phase 4 Pimecrolimus plus topical corticosteroid (TCS);Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
22 Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
23 Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis Completed NCT00693693 Phase 4 hydrocortisone 17-butyrate 0.1% Cream preparation;hydrocortisone 17-butyrate 0.1% Ointment preparation;hydrocortisone 17-butyrate 0.1% Lipocream preparation
24 Protopic Ointment in Children Atopic Eczema Completed NCT00689832 Phase 4 Tacrolimus 0.03%;Fluticasone 0.005%
25 Evaluating Treatment Resistant Dermatitis TaroIIR Completed NCT03050294 Phase 4 Desoximetasone 0.25% spray
26 Protopic Ointment in Adult Atopic Eczema of the Face Completed NCT00690105 Phase 4 tacrolimus 0.1%;fluticasone 0.005 %
27 Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens Completed NCT00557284 Phase 4 Montelukast;Placebo
28 Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis Completed NCT01077882 Phase 4
29 Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children Terminated NCT00810862 Phase 4 pimecrolimus active cream
30 Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis Completed NCT00673725 Phase 4 Locobase® REPAIR
31 Comparison of Two Different Skin Creams and Their Effect on Transepidermal Water Loss (TEWL) in Pediatric Patients With Atopic Dermatitis Not yet recruiting NCT03663673 Phase 4 EpiCeram;Aveeno Daily Moisturising Sheer Hydration Lotion®
32 Can Vitamin D Treatment Help Treat Moderate to Severe Atopic Dermatitis in Young Children? The D-Vex Pilot Study Recruiting NCT03257215 Phase 4 Stoss vitamin D;Daily vitamin D;Stoss placebo;Daily placebo
33 A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis Completed NCT00568412 Phase 4 Elidel
34 Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit Completed NCT00654355 Phase 4 tacrolimus ointment
35 Elidel-Study: Elidel in Patients With Atopic Dermatitis Completed NCT00180141 Phase 4 Elidel-Creme
36 Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis. Completed NCT01177566 Phase 4 pimecrolimus
37 Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis Completed NCT00690833 Phase 4 topical desonide hydrogel 0.05%
38 A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis Completed NCT00106496 Phase 4 Protopic;Corticosteroid;placebo
39 Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis Completed NCT00367393 Phase 4 Pimecrolimus cream 1%
40 A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal Terminated NCT02317276 Phase 4 Triamcinolone 0.1%
41 Epiceram™ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis Completed NCT00616538 Phase 4 Fluticasone Propionate 0.05%
42 Combination Therapy for Atopic Dermatitis Completed NCT00119158 Phase 4 Combination of pimecrolimus and fluticasone;pimecrolimus
43 Management of Pruritus With Xyzal in Atopic Dermatitis Completed NCT00884325 Phase 4 Levocetirizine dihydrochloride (Xyzal);placebo
44 Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification Terminated NCT00124709 Phase 4 Pimecrolimus;Corticosteroid
45 Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis Completed NCT00185510 Phase 4 Methylprednisolone Aceponate (Advantan, BAY86-4862);Placebo
46 Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis Recruiting NCT03293030 Phase 4 Dupilumab
47 Trial on Effectiveness Combined Probiotics in Atopic Dermatitis in Children Completed NCT02519556 Phase 4 Probiatop;Placebo
48 Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis Completed NCT00460083 Phase 4 Elidel(R) (pimecrolimus 1%)
49 A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis Completed NCT00484003 Phase 4 Pimecrolimus cream 1%
50 Prednisolone vs. Ciclosporine in Severe Atopic Eczema Completed NCT00445081 Phase 4 Prednisolone;Ciclosporine A

Search NIH Clinical Center for Dermatitis, Atopic

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: dermatitis, atopic

Genetic Tests for Dermatitis, Atopic

Genetic tests related to Dermatitis, Atopic:

# Genetic test Affiliating Genes
1 Dermatitis, Atopic 29

Anatomical Context for Dermatitis, Atopic

MalaCards organs/tissues related to Dermatitis, Atopic:

41
Skin, Testes, T Cells, Colon, Monocytes, Heart, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatitis, Atopic:

19
The Skin

Publications for Dermatitis, Atopic

Articles related to Dermatitis, Atopic:

(show top 50) (show all 3707)
# Title Authors Year
1
A CCR4 antagonist ameliorates atopic dermatitis-like skin lesions induced by dibutyl phthalate and a hydrogel patch containing ovalbumin. ( 30551395 )
2019
2
A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. ( 30554600 )
2019
3
"Tar smarts" may have a new meaning for atopic dermatitis and psoriasis. ( 30395913 )
2019
4
Atopic Dermatitis: New Developments. ( 30466683 )
2019
5
Mechanisms by Which Atopic Dermatitis Predisposes to Food Allergy and the Atopic March. ( 30479073 )
2019
6
Recall dermatitis at patch test sites in an atopic dermatitis patient treated with dupilumab. ( 30334260 )
2019
7
Therapies in Canine Atopic Dermatitis: An Update. ( 30262146 )
2019
8
Alopecia areata after dupilumab for atopic dermatitis. ( 29387767 )
2018
9
The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with SevereA Itch. ( 29317264 )
2018
10
Could conjunctivitis in dupilumab treated atopic dermatitis patients be caused by colonization with Demodex and increased IL-17 levels? Reply from authors. ( 29336016 )
2018
11
Increased interleukin-36I^ expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/SAczary syndrome. ( 29314201 )
2018
12
A 8-year population-based cohort study of irritable bowel syndrome in childhood with history of atopic dermatitis. ( 29374025 )
2018
13
Validation of patient-reported global severity of atopic dermatitis in adults. ( 28905999 )
2018
14
Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and childhood atopic dermatitis: a prospective birth cohort study. ( 29343261 )
2018
15
Identification and interaction analysis of key genes and microRNAs in atopic dermatitis by bioinformatics analysis. ( 29974487 )
2018
16
Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis. ( 29966024 )
2018
17
Cardiovascular disease and atopic dermatitis: epidemiological strengths and limitations. ( 29971775 )
2018
18
Breast abscess caused by <i>Staphylococcus aureus</i> in 2 adolescent girls with atopic dermatitis. ( 29963104 )
2018
19
An approach on the potential use of probiotics in the treatment of skin conditions: acne and atopic dermatitis. ( 29676446 )
2018
20
IgE-expressing memory B cells and plasmablasts are increased in blood of children with asthma, food allergy and atopic dermatitis. ( 29380876 )
2018
21
Impact of dupilumab on health-related quality of life in patients with atopic dermatitis. ( 29441557 )
2018
22
Enolase-1 expression in the stratum corneum is elevated with parakeratosis of atopic dermatitis and disrupts the cellular tight junction barrier in keratinocytes. ( 29430682 )
2018
23
Fecal Microbiome and Food Allergy in Pediatric Atopic Dermatitis: A Cross-Sectional Pilot Study. ( 29393195 )
2018
24
Online education improves pediatric residents' understanding of atopic dermatitis. ( 29193379 )
2018
25
Cause-specific mortality in adults with atopic dermatitis. ( 29102489 )
2018
26
Atopic dermatitis in Chinese patients shows T<sub>H</sub>2/T<sub>H</sub>17-skewing with psoriasiform features. ( 29964056 )
2018
27
JAK inhibitors appear to have a bright future in the treatment of atopic dermatitis. ( 29441552 )
2018
28
Duration of topical therapy in the maintenance of atopic dermatitis remission in paediatric age. ( 29968448 )
2018
29
Cytokine Targeted Therapeutics forA Alopecia Areata: Lessons fromA Atopic Dermatitis and OtherA Inflammatory Skin Diseases. ( 29273110 )
2018
30
Conjunctivitis Occurring in Atopic Dermatitis Patients Treated with Dupilumab - Clinical Characteristics and Treatment. ( 29432961 )
2018
31
Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model. ( 29970189 )
2018
32
Microbiome analysis of forehead skin in patients with atopic dermatitis and healthy subjects: Implication of Staphylococcus and Corynebacterium. ( 29971837 )
2018
33
Case of atopic dermatitis concurrent with idiopathic thrombocytopenic purpura, whose serum thymus and activation-regulated chemokine level remained undetectable. ( 29399856 )
2018
34
Substance P restores normal skin architecture and reduces epidermal infiltration of sensory nerve fiber in TNCB-induced atopic dermatitis-like lesions in NC/Nga mice. ( 29269174 )
2018
35
Eyelash length for the diagnosis of atopic dermatitis and ichthyosis vulgaris in children-a case control study. ( 29675643 )
2018
36
Serum levels of squamous cell carcinoma antigens 1 and 2 reflect disease severity and clinical type of atopic dermatitis in adult patients. ( 28734739 )
2018
37
Atopic dermatitis: the skin barrier and beyond. ( 29969827 )
2018
38
Lymphopenia in atopic dermatitis patients treated with oral immunosuppressive drugs. ( 29526121 )
2018
39
Eosinophils determine dermal thickening and water loss in a MC903 model of atopic dermatitis. ( 29964034 )
2018
40
Stand-alone Emollient Treatment Reduces Flares After Discontinuation of Topical Steroid Treatment in Atopic Dermatitis: A Double-blind, Randomized, Vehicle-controlled, Left-right Comparison Study. ( 29335742 )
2018
41
Very early introduction of semisolid foods in preterm infants does not increase food allergies or atopic dermatitis. ( 29981439 )
2018
42
Drug survival and post-drug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine. ( 29444359 )
2018
43
Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. ( 29273118 )
2018
44
Juniperus chinensis Fruits Attenuate Oxazolone- and 2,4-Dinitrochlorobenzene-Induced Atopic Dermatitis Symptoms in Mice. ( 29386485 )
2018
45
A cross-sectional study of YouTube videos about atopic dermatitis. ( 29447681 )
2018
46
Is atopic dermatitis associated with obesity? A systematic review of observational studies. ( 29444366 )
2018
47
Altered lipid properties of the stratum corneum in Canine Atopic Dermatitis. ( 29175102 )
2018
48
A case of atopic dermatitis caused by <i>Ascaris lumbricoides</i> infection. ( 29651227 )
2018
49
Ultraviolet A Eye Irradiation Ameliorates Atopic Dermatitis via p53 and Clock Gene Proteins in NC/Nga Mice. ( 29105092 )
2018
50
Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis. ( 29971354 )
2018

Variations for Dermatitis, Atopic

ClinVar genetic disease variations for Dermatitis, Atopic:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 KCNJ11 NM_000525.3(KCNJ11): c.185C> G (p.Thr62Arg) single nucleotide variant Likely pathogenic rs1057518775 GRCh38 Chromosome 11, 17387907: 17387907
2 KCNJ11 NM_000525.3(KCNJ11): c.185C> G (p.Thr62Arg) single nucleotide variant Likely pathogenic rs1057518775 GRCh37 Chromosome 11, 17409454: 17409454
3 CYP4F22 NM_173483.3(CYP4F22): c.1211T> C (p.Leu404Pro) single nucleotide variant Uncertain significance GRCh38 Chromosome 19, 15548182: 15548182
4 CYP4F22 NM_173483.3(CYP4F22): c.1211T> C (p.Leu404Pro) single nucleotide variant Uncertain significance GRCh37 Chromosome 19, 15658993: 15658993
5 CYP4F22 NM_173483.3(CYP4F22): c.1544G> T (p.Arg515Leu) single nucleotide variant Uncertain significance GRCh38 Chromosome 19, 15551419: 15551419
6 CYP4F22 NM_173483.3(CYP4F22): c.1544G> T (p.Arg515Leu) single nucleotide variant Uncertain significance GRCh37 Chromosome 19, 15662230: 15662230

Expression for Dermatitis, Atopic

Search GEO for disease gene expression data for Dermatitis, Atopic.

Pathways for Dermatitis, Atopic

Pathways related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.54 CCL17 FCER2 IL13 IL31 IL4 IL4R
2
Show member pathways
12.73 IL13 IL4 IL4R IL5 MS4A2 RNASE3
3
Show member pathways
12.43 IL13 IL4 IL4R IL5
4
Show member pathways
12.42 IL13 IL4 IL5 MS4A2
5
Show member pathways
12.26 IL13 IL4 IL4R IL5 TSLP
6
Show member pathways
12.19 CCL17 IL13 IL4 IL5
7
Show member pathways
11.93 CCL17 IL13 IL4 IL4R IL5
8 11.81 FCER2 IL13 IL4 IL4R
9 11.67 IL13 IL4 IL5
10 11.66 FCER2 IL4 IL4R IL5
11 11.59 CCL17 IL13 IL4
12 11.53 IL13 IL4 IL5 TSLP
13 11.4 FCER2 IL13 IL4
14 11.36 CMA1 IL13 IL4 IL5
15 11.17 IL4 IL4R IL5
16 11.15 CCL17 FCER2 IL4 IL4R IL5
17 11.08 CCL17 IL13 IL4 IL5
18 11.07 IL13 IL4 IL5
19 11 IL13 IL4 IL5
20 10.96 IL13 IL4 IL5 TSLP
21 10.76 CCL17 IL13 IL31 IL4 IL4R IL5

GO Terms for Dermatitis, Atopic

Cellular components related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CCL17 CMA1 FCER2 IL13 IL31 IL4
2 extracellular space GO:0005615 9.32 CCL17 CMA1 IL13 IL31 IL4 IL4R

Biological processes related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.81 CCL17 IL13 IL5 MS4A2
2 immune response GO:0006955 9.73 CCL17 IL13 IL4 IL4R IL5 MS4A2
3 positive regulation of cold-induced thermogenesis GO:0120162 9.67 IL13 IL4 IL4R
4 regulation of signaling receptor activity GO:0010469 9.63 CCL17 IL13 IL31 IL4 IL5 TSLP
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 IL13 IL4 TSLP
6 positive regulation of B cell proliferation GO:0030890 9.54 IL13 IL4 IL5
7 positive regulation of interleukin-13 production GO:0032736 9.48 IL4 TSLP
8 positive regulation of mast cell degranulation GO:0043306 9.46 IL13 IL4R
9 positive regulation of immunoglobulin production GO:0002639 9.4 IL13 IL4R
10 negative regulation of complement-dependent cytotoxicity GO:1903660 9.32 IL13 IL4
11 positive regulation of macrophage activation GO:0043032 9.13 IL13 IL4R MIR155
12 cytokine-mediated signaling pathway GO:0019221 9.1 FCER2 IL13 IL31 IL4 IL4R IL5

Molecular functions related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 IgE binding GO:0019863 9.16 FCER2 MS4A2
2 cytokine receptor binding GO:0005126 9.13 IL13 IL31 IL4
3 cytokine activity GO:0005125 9.1 CCL17 IL13 IL31 IL4 IL5 TSLP

Sources for Dermatitis, Atopic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR